How much funding has Vicinitas Therapeutics raised?

Vicinitas Therapeutics has raised $65.0M in total funding, most recently a Series A round.

Who are Vicinitas Therapeutics's investors?

Vicinitas Therapeutics's investors include Andreessen Horowitz, Deerfield Management, Droia Ventures, GV, The Mark Foundation for Cancer Research, Berkeley Catalyst Fund.

When was Vicinitas Therapeutics founded?

Vicinitas Therapeutics was founded in 2022.

Where is Vicinitas Therapeutics headquartered?

Vicinitas Therapeutics is headquartered in South San Francisco, California, United States.

What industry is Vicinitas Therapeutics in?

Vicinitas Therapeutics operates in Biotech, Healthcare.

How many employees does Vicinitas Therapeutics have?

Vicinitas Therapeutics has 11-50 employees.

Vicinitas Therapeutics

South San Francisco, United States · Founded 2022 · $65.0M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: vicinitatx.com
Total Funding: $65.0M
Last Round: $65.0M Series AJul 2022
Rounds: 1

About

Vicinitas Therapeutics is a biotechnology company developing precision medicines based on targeted protein stabilization. Its proprietary platform uses Deubiquitinase Targeting Chimeras (DUBTACs) — small molecules that rescue proteins erroneously tagged for degradation by the cell's ubiquitin-proteasome system, restoring healthy protein levels rather than destroying disease-causing proteins as most targeted-protein-degradation approaches do. The science was pioneered in Daniel Nomura's laboratory at UC Berkeley. Vicinitas targets diseases driven by the loss of functional proteins, including cancers and genetic disorders such as cystic fibrosis. The company launched in July 2022 with a $65 million Series A financing co-led by Andreessen Horowitz (a16z) and Deerfield Management, with participation from Droia Ventures and the Berkeley Catalyst Fund. It is based in the San Francisco Bay Area.

Summary

Vicinitas Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2022. It has raised $65.0M in total across 1 round, most recently a $65.0M Series A round in Jul 2022. Investors include Andreessen Horowitz, Deerfield Management and Droia Ventures.